RVNC - Revance Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Nashville,
United States
Type: Equity
RVNC price evolution
RVNC
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $81.73 | $133.16 | $137.88 | |
| Short term investments | $150.79 | $144.46 | $116.59 | |
| Net receivables | $48.26 | $36.09 | $29.89 | $27.68 |
| Inventory | $85.21 | $68.29 | $50.28 | $45.58 |
| Total current assets | $329.69 | $350.17 | $369.69 | $338.87 |
| Long term investments | $5.89 | $5.89 | $6.87 | |
| Property, plant & equipment | $76.99 | $92.61 | $87.75 | $90.21 |
| Goodwill & intangible assets | $8.18 | $8.72 | $9.81 | |
| Total noncurrent assets | $144.63 | $138.43 | $139.59 | |
| Total investments | $156.69 | $150.36 | $123.46 | |
| Total assets | $461.56 | $494.8 | $508.12 | $478.45 |
| Current liabilities | ||||
| Accounts payable | $12.34 | $4.99 | $5.28 | $13.81 |
| Deferred revenue | $77.58 | $81.19 | $81.16 | |
| Short long term debt | $31.61 | $12.13 | $10.85 | |
| Total current liabilities | $80.05 | $93.63 | $68.9 | $89.22 |
| Long term debt | $421.04 | $460.03 | $463.65 | $467.58 |
| Total noncurrent liabilities | $530.9 | $537.89 | $540.83 | |
| Total debt | $491.64 | $475.78 | $478.43 | |
| Total liabilities | $624.59 | $624.54 | $606.79 | $630.06 |
| Shareholders' equity | ||||
| Retained earnings | -$2207.1 | -$2168.99 | -$2131.51 | -$2078.36 |
| Other shareholder equity | $0.07 | -$0.03 | -$0.03 | $0.01 |
| Total shareholder equity | -$129.74 | -$98.67 | -$151.6 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $137.88 | $115.02 | $115.67 | $337 |
| Short term investments | $116.59 | $231.74 | $114.45 | $102.95 |
| Net receivables | $27.68 | $11.34 | $3.35 | $1.83 |
| Inventory | $45.58 | $18.32 | $10.15 | $5.88 |
| Total current assets | $338.87 | $374.73 | $246.12 | $450 |
| Long term investments | $6.87 | |||
| Property, plant & equipment | $90.21 | $67.75 | $69 | $47.13 |
| Goodwill & intangible assets | $9.81 | $104.18 | $202.3 | $218.31 |
| Total noncurrent assets | $139.59 | $207.17 | $285.05 | $270.22 |
| Total investments | $123.46 | $231.74 | $114.45 | $102.95 |
| Total assets | $478.45 | $581.9 | $531.16 | $720.22 |
| Current liabilities | ||||
| Accounts payable | $13.81 | $4.55 | $10.6 | $12.66 |
| Deferred revenue | $81.16 | $85.44 | $83.51 | $85.14 |
| Short long term debt | $10.85 | $4.91 | $4.75 | $4.44 |
| Total current liabilities | $89.22 | $75.68 | $67.29 | $60.96 |
| Long term debt | $467.58 | $379.37 | $319.77 | $207.67 |
| Total noncurrent liabilities | $540.83 | $493.62 | $395.4 | $284.97 |
| Total debt | $478.43 | $418.47 | $324.51 | $212.11 |
| Total liabilities | $630.06 | $569.3 | $462.69 | $345.93 |
| Shareholders' equity | ||||
| Retained earnings | -$2078.36 | -$1754.37 | -$1397.95 | -$1126.29 |
| Other shareholder equity | $0.01 | -$0.37 | -$0.02 | |
| Total shareholder equity | -$151.6 | $12.6 | $68.47 | $374.29 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $59.88 | $65.39 | $51.94 | $69.8 |
| Cost of revenue | $17.64 | $14.91 | $17.47 | |
| Gross Profit | $42.25 | $47.75 | $37.02 | $52.33 |
| Operating activities | ||||
| Research & development | $15.9 | $14.39 | $20.37 | |
| Selling, general & administrative | $65.82 | $68.91 | $85.24 | |
| Total operating expenses | $74.5 | $82.27 | $83.85 | $106.28 |
| Operating income | -$34.52 | -$46.83 | -$53.95 | |
| Income from continuing operations | ||||
| EBIT | -$31.79 | -$47.9 | -$50.3 | |
| Income tax expense | $1.5 | |||
| Interest expense | -$4.1 | $5.68 | $5.26 | $5.4 |
| Net income | ||||
| Net income | -$38.12 | -$37.47 | -$53.15 | -$55.7 |
| Income (for common shares) | -$37.47 | -$53.15 | -$55.7 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $234.04 | $132.56 | $77.8 | $15.32 |
| Cost of revenue | $74.36 | $51.67 | $23.41 | $4.77 |
| Gross Profit | $159.68 | $80.9 | $54.39 | $10.56 |
| Operating activities | ||||
| Research & development | $79.41 | $101.29 | $116.25 | $125.8 |
| Selling, general & administrative | $297.73 | $223.93 | $198.82 | $151.85 |
| Total operating expenses | $476.45 | $422.86 | $329.06 | $283.72 |
| Operating income | -$316.78 | -$341.96 | -$274.68 | -$273.16 |
| Income from continuing operations | ||||
| EBIT | -$304.33 | -$339.25 | -$275.04 | -$269.56 |
| Income tax expense | $0.3 | $0.7 | -$2.62 | |
| Interest expense | $19.36 | $16.47 | $6.27 | $15.15 |
| Net income | ||||
| Net income | -$323.99 | -$356.42 | -$281.31 | -$282.09 |
| Income (for common shares) | -$323.99 | -$356.42 | -$281.31 | -$282.09 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$37.47 | -$53.15 | -$55.7 | |
| Operating activities | ||||
| Depreciation | $1.43 | $1.98 | $1.42 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $5.79 | $8.99 | $8.85 | |
| Total cash flows from operations | -$41.13 | -$65.94 | -$42.73 | |
| Investing activities | ||||
| Capital expenditures | -$0.47 | -$1.71 | -$1.78 | |
| Investments | -$6.42 | -$30 | $4.15 | |
| Total cash flows from investing | -$15.3 | -$6.89 | -$31.71 | $2.37 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.56 | $97.65 | $1.26 | |
| Net borrowings | -$3.9 | -$4.23 | -$2.74 | |
| Total cash flows from financing | $83.33 | -$3.41 | $92.83 | -$1.63 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$80.14 | -$51.43 | -$4.82 | -$41.99 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$323.99 | -$356.42 | -$281.31 | -$282.09 |
| Operating activities | ||||
| Depreciation | $13.69 | $39.15 | $19.85 | $10.25 |
| Business acquisitions & disposals | -$0.82 | |||
| Stock-based compensation | $47.81 | $52.34 | $43.43 | $36.45 |
| Total cash flows from operations | -$216.57 | -$193.55 | -$221.54 | -$178.5 |
| Investing activities | ||||
| Capital expenditures | -$6.89 | -$3.21 | -$10.38 | -$4.22 |
| Investments | $116.63 | -$135.59 | -$19.29 | $17.16 |
| Total cash flows from investing | $109.74 | -$138.8 | -$29.66 | $12.13 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $115.47 | $252.83 | $38.39 | $90.84 |
| Net borrowings | $29.31 | $85.01 | $278.31 | |
| Total cash flows from financing | $136.57 | $331.69 | $29.87 | $331.48 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $29.73 | -$0.65 | -$221.33 | $165.11 |
News
Fundamentals
| Market cap | $382.87M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 104.90M |
| Revenue | $247.00M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$184.44M |
| Revenue Q/Q | 5.47% |
| Revenue Y/Y | 15.33% |
| P/E ratio | -2.08 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 1.55 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$1.76 |
|---|---|
| ROA | -37.97% |
| ROE | N/A |
| Debt/Equity | -4.16 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 4.12 |
| Quick ratio | 3.05 |